Gene expression profiling of primary HER2-positive breast cancers treated with neoadjuvant trastuzumab
Ontology highlight
ABSTRACT: Trastuzumab, a humanized monoclonal antibody directed to the HER2 protein, is the standard-of-care treatment for patients with HER2 positive breast cancer, reducing the risk of relapse and death in patients. Nonetheless, some patients do not benefit from this treatment, underscoring the need to identify patients for whom chemotherapy + trastuzumab is adequate versus patients requiring additional drugs. The series comprised 18 incisional biopsies of breast carcinomas derived from patients that received neoadjuvant trastuzumab based therapy.
ORGANISM(S): Homo sapiens
PROVIDER: GSE149283 | GEO | 2021/12/31
REPOSITORIES: GEO
ACCESS DATA